Medical Technology Breaking News: Aethlon Medical
(OTCQB: AEMD) Announces Nasdaq Capital Market Listing Approval
SAN DIEGO - July 8, 2015 (Investorideas.com
newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat
life-threatening diseases, today announced that the Company's application to
list its common stock on the Nasdaq Capital Market has been approved by The
NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on
the Nasdaq Capital Market at the opening of market hours on Monday, July 13,
2015 under its existing trading symbol, AEMD.
"Trading on Nasdaq is a pivotal corporate milestone that
will help raise the visibility of our therapeutic endeavors and increase the
appeal of our shares to mutual funds, pension funds, and other institutional
investors that may have previously been restricted from trading our
shares," stated Jim Joyce, Chairman and CEO of Aethlon Medical.
About Aethlon Medical, Inc.
Aethlon
Medical creates affinity biofiltration devices to treat life-threatening
diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a
first-in-class device that targets the rapid elimination of infectious viruses
and cancer-promoting exosomes from the circulatory system of treated individuals.
U.S. clinical progression of Hemopurifier therapy is being advanced under an
FDA approved clinical study. We also provide government contracting services to
the Defense Advanced Research Projects Agency related to the development of a
biofiltration device to treat sepsis. Additional information can be found
online at www.AethlonMedical.com or you can connect with us on on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
No comments:
Post a Comment